Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 5/20 | 0.59 |
| ▸ | ITGA2B known ✓ | P08514 | 5/20 | 0.59 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LSS | P48449 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742952 | 0.98 | ITGB3 (0.60) | ITGB3ITGA2BNOTUMKDM4ECYP2C19 | |
| Trifluoroacetic Acid SCHEMBL1648792 | 0.89 | ITGB3 (0.56) | ITGB3ITGA2BNOTUMKDM4ECYP2C19 | |
| SCHEMBL8838123 | 0.86 | ITGB3 (0.70) | ITGB3ITGA2BCYP2C19LSSAKR1C3 | |
| Hydrochloric Acid SCHEMBL6798939 | 0.85 | LSS (0.49) | ITGB3ITGA2BLSSAKR1C3CHKA | |
| Hydrochloric Acid SCHEMBL6969582 | 0.84 | NOTUM (0.77) | NOTUMKDM4ECYP2C19AKR1C3 | |
| Hydrochloric Acid SCHEMBL28125955 | 0.84 | NOTUM (0.77) | NOTUMKDM4ECYP2C19AKR1C3 | |
| Hydrochloric Acid SCHEMBL7354737 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BNOTUMKDM4ECYP2C19 | |
| SCHEMBL16887557 | 0.83 | CYP2C9 (0.53) | ITGB3ITGA2BLSSCHKAHRH3 | |
| SCHEMBL3166233 | 0.83 | LSS (0.50) | ITGB3ITGA2BNOTUMLSSCHKA | |
| SCHEMBL2780304 | 0.83 | CYP3A4 (0.54) | ITGB3ITGA2BKDM4ELSSCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-115175894-A | Nano material | 盖德治疗有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210230112-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-8227506-B2 | Benzamidine compound | AJINOMOTO., INC. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | AJINOMOTO CO. INC (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20020193348-A1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1236735-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| CN-1311771-A | Benzamidine derivative | AJINOMOTO KK (JP) | 2001-09-05 | — | — | CN | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105731-A2 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | ITGB3 1525/4885ITGA2B 332/4885HRH3 722/4885 |
| US-20210230112-A1 | NANOMATERIALS | NPC1, NPC1L1, FABP1 | ITGB3 938/4885ITGA2B 383/4885HRH3 4168/4885 |
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | ITGB3 671/4885ITGA2B 424/4885HRH3 728/4885 |
| US-20020193348-A1 | Benzamidine derivatives | SERPINC1, SERPINE1, TFPI | ITGB3 1662/4885ITGA2B 820/4885HRH3 814/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | ITGB3 229/4885ITGA2B 177/4885HRH3 1362/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | ITGB3 1420/4885ITGA2B 1579/4885HRH3 4204/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | ITGB3 938/4885ITGA2B 383/4885HRH3 4168/4885 |
| US-20080021065-A1 | NOVEL BENZAMIDINE COMPOUND | SERPINC1, F11, TFPI | ITGB3 1525/4885ITGA2B 332/4885HRH3 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.